Results 31 to 40 of about 106,748 (296)

CD20 expression in the transplanted kidney of patients with graft loss and transient allograft dysfunction [PDF]

Journal of Medical Biochemistry, 2012
This study aimed to explore the relationship between the infiltration of CD20+ B cells and the survival time of a renal allograft and to investigate the role of infiltrated B cells in the rejection of the renal allograft.
Han Yong, Shi Bingyi, Cai Ming, Xiaoguang Xu, Liang Xu, Wang Qiang, Zhou Wenqiang, Xiao Li   +7 more
doaj  

Progressive Encephalomyelitis with Rigidity and Myoclonus Treated with Rituximab: Case Report and Review of the Literature

Brown Journal of Hospital Medicine, 2022
A woman in her 50s presented with hyper-religiosity, auditory hallucinations, episodes of staring associated with unresponsiveness and stiffening of her entire body. A broad workup excluded autoimmune encephalitis, sarcoidosis, and prion disease. She was
Carlin Chuck, Karl Herman, Sleiman El Jamal   +2 more
doaj   +1 more source

Monoclonal antibodies targeting CD20 [PDF]

mAbs, 2013
Letter to the Editor: We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of this journal.1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20+ hematological ...
Chang, Chien-Hsing, Rossi, Edmund A., Goldenberg, David M.   +2 more
openaire   +2 more sources

Features of Human CD3(+)CD20(+) T Cells [PDF]

, 2016
Monoclonal Abs against CD20 reduce the number of relapses in multiple sclerosis (MS); commonly this effect is solely attributed to depletion of B cells. Recently, however, a subset of CD3(+)CD20(+) T cells has been described that is also targeted by the ...
Krane, M., Feil, K., Berer, K., Schuh, E., Pfannes, K., Krumbholz, M., Lange, R., Kuempfel, T., Hohlfeld, R., Mulazzani, M., Lahm, H., Subklewe, M., Meinl, E., Guerkov, R., Bradl, M., Meinl, I.   +15 more
core   +1 more source

Immunohistochemical analysis of PD-L1, CD4, CD8, CD20, and PU.1 expression in a dedifferentiated chondrosarcoma: the clinical and prognostic value

Alʹmanah Kliničeskoj Mediciny
Background: Dedifferentiated chondrosarcoma (DDCS) is a rare and extremely aggressive variant of mesenchymal bone tumors, with a biphasic structure represented by the classical chondrosarcoma elements, usually of low or intermediate grade, combined with ...
Olga V. Kovaleva, Irena V. Boulytcheva, Dmitrii V. Rogozhin, Alexei N. Gratchev, Polina L. Prishchep, Nikolay E. Kushlinskii   +5 more
doaj   +1 more source

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

, 2010
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance ...
French, R.R., Johnson, P.W.M., Cox, Kerry L., Chan, Claude H.T., Johnston, David A., Glennie, Martin J., Jarrett, T.C., Glennie, M.J., Verbeek, Sjef, Chan, H.T.C., Dixon, S.V., Mora Vidal, Regina, Wijayaweera, Sahan S., Cragg, Mark S., Lim, Sean H., Dixon, Sandra V., Verbeek, J.S., French, Ruth R., Wijayaweera, S.S., Jarrett, Timothy C., Cragg, M.S., Kim, Hyung J., Kerr, Jonathan P., Vidal, R.M., Johnston, D.A., Lim, S.H., Cox, K.L., Kerr, J.P., Johnson, Peter W.M., Beers, Stephen A., Kim, H., Beers, S.A.   +31 more
core   +1 more source

Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes [PDF]

, 2009
Peptide mimotopes of the CD20 epitope recognized by rituximab are useful tools for studying this therapeutic mAb's functional properties. We previously identified two structurally different peptides that are both effective mimotopes: a 7-mer cyclic ...
Guarnera A, Dammacco F., FAVOINO, ELVIRA, De Pinto V, PEROSA, Federico, Vicenti C, RACANELLI, Vito   +6 more
core   +1 more source

Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma [PDF]

Journal of Pathology and Translational Medicine, 2016
Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximab-containing chemotherapy.
Chang Hwan Choi, Young Hoon Park, Joo Han Lim, Suk Jin Choi, Lucia Kim, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu   +8 more
doaj   +1 more source

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy

OncoImmunology, 2018
Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating
Beata Pyrzynska, Michal Dwojak, Abdessamad Zerrouqi, Giulia Morlino, Piotr Zapala, Nina Miazek, Agnieszka Zagozdzon, Kamil Bojarczuk, Malgorzata Bobrowicz, Marta Siernicka, Marcin M. Machnicki, Stefania Gobessi, Joanna Barankiewicz, Ewa Lech-Maranda, Dimitar G. Efremov, Przemyslaw Juszczynski, Dinis Calado, Jakub Golab, Magdalena Winiarska   +18 more
doaj   +1 more source

Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma [PDF]

, 2007
We report the first case of diffuse large B-cell lymphoma (DLBCL) of the stomach displaying CD20-negative relapse after rituximab-containing treatment and the re-appearance of CD20 expression at the second failure.
C. Doglioni, G.P. Dognini, A.J. Ferreri, C. Verona, M. Ponzoni, C. Patriarca   +5 more
core   +1 more source